| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Business Officer
1 company
Chakma Justin serves as a Chief Business Officer at SPRY. Across recent SEC filings that breaks down to 0 buys and 13 sells.
Historically, Chakma Justin's trades have earned a strong insider score of 81/100 across 12 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +27.6%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2025 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 166,380 | $8.87 | $1,476,147.49 | - | +10.9% | - | |
| Dec 13, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 144,605 | $12.23 | $1,768,092.94 | -51.5% | +0.4% | -13.9% | |
| Dec 10, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 50,000 | $13.15 | $657,625.00 | -26.8% | -16.4% | -19.4% | |
| Dec 6, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 144,640 | $14.11 | $2,041,200.04 | -51.5% | -23.0% | -29.2% | |
| Dec 3, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sale+OE | 90,000 | $13.43 | $1,208,619.00 | -39.8% | -25.2% | -29.8% | |
| Nov 27, 2024 | SPRY Ars Pharmaceuticals, Inc. | Chief Business Officer | Sell | 100,000 | $14.12 | $1,411,742.12 | -42.3% | -27.3% | -34.3% |